US-based BostonGene, developer of the leading AI foundation model for tumour and immune biology, has announced the expanded strategic research collaboration with Japan’s Hokkaido University.
This multi-year initiative is designed to produce actionable, high-quality, clinically relevant data that support the development of precision therapies and ultimately improve outcomes for cancer patients in Japan.
In collaboration with Hokkaido University, BostonGene will conduct next-generation sequencing and perform integrated analysis of DNA, RNA and immune system profiling using its proprietary AI-powered platform to analyse genomic and immune profiles from tumor samples across more than 20 cancer types. These analyses will help identify patient-specific disease drivers, profile underlying immune signatures, and guide optimal therapeutic decision-making.
“BostonGene’s AI-powered platform gives us the advanced analytics needed to turn clinical data into actionable insights,” said Dr Ichiro Kinoshita, Principal Investigator and Professor at the Division of Clinical Cancer Genomics/Department of Medical Oncology at Hokkaido University, and Dr Yutaka Hatanaka, Associate Professor at the Center for Development of Advanced Diagnostics (C-DAD), Institute of Health Science Innovation for Medical Care, Hokkaido University Hospital. “By contributing our scientific expertise and patient samples, we’re driving a more personalised, effective approach to oncology for Japanese patients.
“This partnership exemplifies how BostonGene’s AI-driven insights translate complex patient data into meaningful advances in drug development and clinical care, while reinforcing our commitment to advancing translational oncology in Japan, where there is significant and urgent clinical need,” said Yukimasa Shiotsu, President and Representative Director of BostonGene Japan.
AloJapan.com